Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 157,037 shares, an increase of 959.3% from the January 29th total of 14,825 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 1,130,051 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 1,130,051 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Oncotelic Therapeutics Stock Performance

Shares of OTLC traded up $0.00 during trading hours on Wednesday, hitting $0.05. 154,242 shares of the company were exchanged, compared to its average volume of 360,310. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.11. The firm has a fifty day simple moving average of $0.07 and a 200-day simple moving average of $0.08.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.